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Glucocorticoids promote structural and functional
maturation of foetal cardiomyocytes: a role for PGC-1α
EA Rog-Zielinska1,5, M-A Craig2, JR Manning1, RV Richardson1, GJ Gowans3, DR Dunbar1, K Gharbi4, CJ Kenyon1, MC Holmes1,
DG Hardie3, GL Smith2 and KE Chapman*,1
Glucocorticoid levels rise dramatically in late gestation to mature foetal organs in readiness for postnatal life. Immature heart
function may compromise survival. Cardiomyocyte glucocorticoid receptor (GR) is required for the structural and functional
maturation of the foetal heart in vivo, yet the molecular mechanisms are largely unknown. Here we asked if GR activation in foetal
cardiomyocytes in vitro elicits similar maturational changes. We show that physiologically relevant glucocorticoid levels improve
contractility of primary-mouse-foetal cardiomyocytes, promote Z-disc assembly and the appearance of mature myofibrils, and
increase mitochondrial activity. Genes induced in vitro mimic those induced in vivo and include PGC-1α, a critical regulator of
cardiac mitochondrial capacity. SiRNA-mediated abrogation of the glucocorticoid induction of PGC-1α in vitro abolished the effect
of glucocorticoid on myofibril structure and mitochondrial oxygen consumption. Using RNA sequencing we identified a number of
transcriptional regulators, including PGC-1α, induced as primary targets of GR in foetal cardiomyocytes. These data demonstrate
that PGC-1α is a key mediator of glucocorticoid-induced maturation of foetal cardiomyocyte structure and identify other candidate
transcriptional regulators that may play critical roles in the transition of the foetal to neonatal heart.
Cell Death and Differentiation (2015) 22, 1106–1116; doi:10.1038/cdd.2014.181; published online 31 October 2014
Maturation of foetal tissues in readiness for the transition from
foetal to postnatal life is dependent on the dramatic rise in
glucocorticoid levels shortly before birth.1–3 Hence, potent-
synthetic glucocorticoids are routinely administered to preterm
babies or foetuses at risk of premature birth, to improve
neonatal survival.4 In addition to the beneficial effects of
glucocorticoids on lung maturation, we have recently shown
that glucocorticoids are vital to mature foetal-heart structure
and function. Endogenous glucocorticoids act via glucocorti-
coid receptor (GR) in foetal cardiomyocytes/vascular smooth
muscle to promote myofibril assembly and organisation, thus
advancing systolic function and cardiac ultrastructural organi-
sation in vivo.5 These maturational effects are associated with
mRNA changes in the foetal heart indicative of improved
contractile function, calcium handling and energy metabolism.
However, the genes directly under GR control in cardiomyo-
cytes responsible for these vital changes are unknown.
In foetal mice, levels of the endogenous glucocorticoid,
corticosterone, are negligible in heart at embryonic day (E)
14.5, but rise rapidly once adrenal corticosterone synthesis
begins at E15,6 peaking at E16.5.5,7 Consistent with this, GR
only becomes localised to the nucleus in mouse cardiomyo-
cytes at E15.5, suggesting the key events initiated by GR
activation occur over 24 h or less. Although several studies
have reported glucocorticoid-induced mRNA changes in 24 h
in primary rodent neonatal cardiomyocytes, foetal cardiomyo-
cytes are less mature than neonatal.8 Also, unlike neonatal
cardiomyocytes, foetal cardiomyocytes have not had prior
exposure to high levels of glucocorticoids in utero, which can
alter the response to subsequent glucocorticoid exposure,9
itself highly cell and context dependent.10,11 Moreover, no
previous studies in cardiomyocytes have examined the
primary events initiated by GR activation. Here, we used
primary-mouse-foetal cardiomyocytes to demonstrate direct
actions of glucocorticoids in recapitulating the structural,
functional and biochemical consequences of GR activation
in vivo. Moreover, we have identified genes directly regulated
by GR and show a critical role for induction of the transcrip-
tional coactivator, PGC-1α in the structural maturation of foetal
cardiomyocytes induced by glucocorticoid treatment in vitro.
Results
Primary mouse foetal cardiomyocytes are glucocorticoid
responsive. We first established that mouse foetal cardio-
myocytes in culture contain functional GR. Immunofluorescence
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confirmed nuclear translocation of GR within 1 h of addition of
physiological glucocorticoid, corticosterone, or the potent-
synthetic glucocorticoid, dexamethasone, to cardiomyocytes
isolated from E14.5–E16.5 C57BL/6 mouse foetal hearts
(Supplementary Figure 1B). Levels of Dusp1 and Fkbp5
mRNAs, known GR target genes12,13 were increased following
glucocorticoid treatment (Supplementary Figure 1C).
Corticosterone promotes sarcomeric organisation and
myofibril assembly in foetal cardiomyocytes. Having
confirmed a response to glucocorticoids, we asked whether
glucocorticoid treatment in vitro can mimic the improvement
in myofibrillar structure evoked by GR activation in vivo in
cardiomyocytes.5 Primary foetal cardiomyocytes were treated
with 100 nM corticosterone, approximating levels in the
wild-type late gestation (E16.5–E17.5) foetal heart, for 24 h.
As well as inducing the formation of troponin T-associated
α-smooth muscle actin stress fibres in primary foetal
cardiomyocytes (Supplementary Figure 1D), corticosterone
dramatically altered myofibril organisation, visualised by
staining of α-actinin (Figure 1a), a constituent of myofibrillar
Z-discs. Though Z-disc structures were observed in untreated
cells, they became better defined, aligned, and regularly
distributed throughout cardiomyocytes following the corticos-
terone treatment (Figure 1a). The overall appearance of
myofibrillar structure was improved, and the sarcomere
length (measured as the distance between neighbouring
Z-discs) and Z-disc width were increased following the
corticosterone treatment (Figure 1b). Pre-treatment with the
GR antagonist, RU38486 (RU486), abolished the effect of
corticosterone on myofibrillar structure, demonstrating its
dependence on GR (Figures 1a and b).
Transmission electron microscopy of sections through
primary foetal cardiomyocytes showed a striking increase in
contractile fibres in corticosterone-treated cardiomyocytes
with clearly delineated myofibrils often associated with well-
defined Z-discs (Figure 1c). In contrast, very few Z-discs were
apparent in untreated cells and although some fibrillar material
was present, it was predominantly disorganised and scattered
throughout the cell.
Corticosterone improves contractility of foetal cardio-
myocytes. We next asked, whether the improved myofibrillar
structure is associated with improved function by measuring
the effect of corticosterone on the contractile properties of
primary foetal cardiomyocytes using soft-video edge detec-
tion. Treatment with 100 nM corticosterone for 24 h did not
affect the frequency of spontaneous contractions (Figure 2a;
control 35.1± 1.3 beats/min versus corticosterone 39.0±1.8
beats/min; n=38 cells) but markedly increased contraction
amplitude (Figures 2b and c). Corticosterone also decreased
contraction and relaxation times (bottom-to-peak and peak-
to-bottom time, respectively; Figure 2d) and improved the
relaxation kinetics, measured as the time taken to reach 90%
relaxation (Figure 2e). Thus, structural improvements elicited
by corticosterone are associated with improved contractile
function.
Glucocorticoids via GR regulate candidate gene expression
in cardiomyocytes. To establish that the transcriptional
Figure 1 Corticosterone promotes myofibril maturation in foetal cardiomyocytes in a GR-dependent manner. (a) Representative images of control (untreated) primary foetal
C57BL/6 cardiomyocytes (left panels), or following 100 nM corticosterone (cort) for 24 h (centre panels). To block GR-mediated effects, cells were pre-treated with 1 μM RU38486
(RU486) for 30 min prior to addition of 100 nM corticosterone for 24 h (RU486+cort; right panels). Cells were stained with α-actinin (red, Z-discs) and DAPI (blue, nuclei).
(b) Quantification of the effect of 100 nM cort on myofibrillar structure (top graph, see Materials and Methods for details of the scoring system), sarcomere length (middle graph),
and Z-structure/Z-disc width (bottom graph). Data were analysed by one-way ANOVA with Bonferroni’s post-hoc test; **Po0.01, ***Po0.001 versus control; +Po0.05,
++Po0.01, +++Po0.001 versus cort; n= 50–80 replicates over three independent experiments. (c) Representative transmission electron micrographs of sections of control
primary foetal C57BL/6 mouse cardiomyocytes (left panels), or following 100 nM corticosterone (cort) for 24 h (right panels); arrows, myofibrils; arrowheads, Z discs;
mt, mitochondria; f, fibres; n, nuclei. Images representative of n= 10 cells
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response of primary foetal cardiomyocytes to glucocorticoids
resembles that of the foetal heart, we measured mRNAs
that we have previously shown to be altered in heart by
glucocorticoid action in vivo.5 Tsc22d3 (encoding glucocorticoid-
induced leucine zipper) represents a classical glucocorticoid-
regulated gene, with Myh6 (encoding myosin heavy chain-α;
MyHCα) and Ppargc1a (encoding PPARγ coactivator-1α;
PGC-1α) representative of structural and metabolic genes,
respectively. Nppa (encoding atrial natriuretic peptide) is
known to be glucocorticoid regulated in neonatal rat
cardiomyocytes.8,14 Corticosterone activates GR, but can
also activate mineralocorticoid receptor (MR) in the absence
of 11β-hydroxysteroid dehydrogenase-2.15,16 We therefore
compared the effect of corticosterone with that of dexa-
methasone, which poorly activates MR.16 Dexamethasone
induced all four mRNAs in a dose-dependent manner over
24 h (Figures 3a–d). Similarly, 100–200 nM corticosterone,
approximating concentrations in the late-gestation mouse
heart, increased Tsc22d3, Nppa, and Ppargc1a mRNA levels
(Figures 3e–h). The modest increase in Myh6 mRNA levels
with 100 nM corticosterone was not observed with the higher
dose of 200 nM corticosterone. Glucocorticoid treatment also
induced genes involved in calcium handling: Cacna1c, Ryr2,
Atp2a2, and Slc8a1, encoding respectively, Cav1.2 (voltage-
gated Ca2+ channel), ryanodine receptor-2, SERCA2a
(sarco/endoplasmic reticulum Ca2+ ATP-ase 2a) and NCX1
(Na+/Ca2+ exchanger; Supplementary Figures 2A and D),
consistent with effects of endogenous GR activation in foetal
heart in vivo.5
RU486 antagonism of GR blocked the glucocorticoid
induction of Tsc22d3, Myh6, Nppa, and Ppargc1a mRNAs
(Figure 4) whereas the MR antagonist spironolactone had no
effect (Supplementary Figures 2E and H). Similarly, siRNA
mediated knock-down of GR (80% and 35% reduction in GR
mRNA and protein levels, respectively; Supplementary
Figures 3A and B) attenuated the dexamethasone induction
of these mRNAs (Figure 4) with little or no effect of scrambled
siRNA on dexamethasone-induced transcriptional responses
(Supplementary Figure 3C). These experiments confirm GR
as a crucial mediator of the transcriptional responses to
glucocorticoids in foetal cardiomyocytes. To examine direct
regulation by GR, cycloheximide was administered prior to
dexamethasone, to block new protein synthesis.
Glucocorticoid-induction of Tsc22d3 and Ppargc1a mRNA
was maintained (and increased in the case of Ppargc1a) with
cycloheximide, suggesting these genes are direct targets of
GR in cardiomyocytes (Figures 4a and d). In contrast,
glucocorticoid induction of Myh6 and Nppa mRNAs was
abolished by cycloheximide demonstrating this regulation
depends on new protein synthesis (Figures 4b and c).
RNAseq analysis reveals potential primary glucocorti-
coid targets in cardiomyocytes. The above experiments
suggest GR initiates a transcriptional cascade in foetal
cardiomyocytes, in which master regulators (such as
Tsc22d3 and Ppargc1a) are induced to establish the
maturational programme. To explore the extent of the
glucocorticoid-induced programme and to identify potential
Figure 2 Corticosterone treatment improves the contraction-relaxation of foetal cardiomyocytes. Cells were treated with 100 nM corticosterone for 24 h prior to edge-
detection analysis. (a, b) Representative edge-detection traces showing single contraction (upwards)/relaxation (downwards) events for untreated (control/black) and
corticosterone-treated (cort/red) cells. Corticosterone increased the amplitude of contraction (c), measured as the distance travelled by the cardiomyocyte edge during the
shortening phase, and (d) decreased the time of contraction and relaxation as well as (e) decreased time taken to reach 90% relaxation. Data were analysed by Student’s t-test;
*Po0.05, **Po0.01; n= 38 cells
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master regulators and primary target genes of GR in foetal
heart, next generation RNA sequencing (RNAseq) was
performed on primary foetal cardiomyocytes following treat-
ment with 100 nM dexamethasone for 2 h in the presence of
cycloheximide. Controls were treated with cycloheximide
alone. A total of 613 transcripts covering 564 genes were
differentially expressed (adjusted Po0.05) in glucocorticoid-
treated cardiomyocytes, with 469 transcripts increased and
144 decreased. As expected, the induced genes included
Ppargc1a and Tsc22d3 (Table 1). Gene set enrichment
analysis with gene ontology (GO) terms revealed sequence-
specific DNA binding proteins with transcription factor activity,
and sequence-specific DNA binding proteins to be the two
groups of most over-represented terms affecting molecular
function, representing ~ 9% of differentially expressed genes
(Table 1; see Supplementary Table 1 for the full list). These
include regulators of key pathways including development
and growth (Notch1, Myc, Wt1, Hes1), circadian rhythm
(Per1, Nr1d1), metabolism (Cebpb, Ppara), and hypoxia
(Hif3a, Epas1), several of which are known GR targets in
other cell types (e.g., Hes1, Notch1, Per1, Ppara17–20).
Nr3c1, encoding GR itself, was repressed, though Nr3c2
(encoding MR) was unaffected by dexamethasone. Nr0b2,
encoding small heterodimer partner (SHP), a repressor of
nuclear receptor function and regulator of both PGC-1 and
GR activity,21 was also included in this group. Several
induced genes encode factors implicated in early cardiac
development, including Klf2 and Notch1. Our data suggest
they may also be induced by glucocorticoid to play a later role
in cardiac maturation. Although Klf2 mRNA was unaltered in
hearts of E17.5 GR− /− foetuses,5Klf2 might be transiently
induced in the wild-type heart as corticosterone levels
increase at E15.5, with subsequent negative feedback
returning levels to basal by E17.5. Such temporary increases
in key developmental or transcriptional regulators can lead to
permanent changes in cellular transcriptional programmes,
setting the cell on the path to terminal differentiation.22 It is
also possible these effects on expression of developmental
regulators relates to the in vitro conditions used here.
Other transcriptional regulators, which themselves are not
DNA binding proteins, were differentially expressed. These
include reciprocal regulation of Ppargc1a (increased twofold)
and Ppargc1b (decreased to almost the same extent). Current
evidence suggests PGC-1β plays a redundant role in foetal
heart maturation.23 However, PGC-1β expression declines as
PGC-1α expression increases during cardiomyocyte differ-
entiation of human ES cells (hESC),24 consistent with our
data. Other repressed genes include Bmp4, Hey1, and Efna1,
encoding key regulators of early cardiac differentiation,25–29 in
accordance with the maturational effects of glucocorticoids on
foetal cardiomyocytes.
Other differentially expressed genes include cell surface
growth factor or neurotransmitter receptors as well as several
members of the voltage-gated potassium channel family (e.g.,
Kcna5, Kcnk1, Kcne4, Kcnk5) and subunits of the ENaC
epithelial sodium channel. Members of the voltage-gated
potassium channel family have previously been identified as
glucocorticoid-regulated genes,30–32 supporting their identifi-
cation here as primary targets of GR in foetal cardiomyocytes.
Several members of the Slc family of solute transporters were
differentially expressed suggesting altered transport of small
molecules across membranes. These include four members
of the Slc25 family of mitochondrial carriers, Slc25a25,
Slc25a33, Slc25a18, and Slc25a30, two of which transport
Figure 3 Glucocorticoid treatment of primary foetal cardiomyocytes dose-dependently replicates in vivo regulation of cardiac gene expression by glucocorticoid action.
Treatment of primary foetal C57BL/6 cardiomyocytes for 24 h with dexamethasone (dex) (a–d) or corticosterone (cort) (e–h) dose-dependently increased levels of mRNA
encoding glucocorticoid-induced leucine zipper (GILZ), MyHCα, atrial natriuretic peptide (ANP) and PGC-1α. Data were analysed by one-way ANOVA with Bonferroni post-hoc
test; *Po0.05, **Po0.01, ***Po0.001; n= 5 replicates over two independent experiments
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nucleotides. Thus, glucocorticoids directly affect some aspects
of mitochondrial function whereas other may be secondary to
induction of "master regulators" such as PGC-1α.
PGC-1α mediates the effects of glucocorticoids on
myofibrillar structure and oxygen consumption of cardi-
omyocytes. We validated PGC-1α as an early target of
glucocorticoid action in foetal cardiomyocytes by confirming
dexamethasone induction of Ppargc1a mRNA within 2 h as
well as 8 h of dexamethasone addition. Although steady-state
Ppargc1a mRNA levels increased following addition of
cycloheximide (suggesting rapid turnover of Ppargc1a
mRNA), dexamethasone further increased Ppargc1a mRNA
levels, above those with cycloheximide alone (Supplementary
Figures 3D and E), consistent with Ppargc1a being a direct
target of GR. In vivo, Ppargc1a mRNA levels are reduced in
hearts of GR− /− mice5 and like GR− /− foetuses, mice lacking
PGC-1α and PGC-1α show profound defects in foetal cardiac
maturation with functionally immature hearts and persistence
of a foetal-gene expression pattern, including reduced
expression of Atp2a2 and Myh6.23 Ppargc1a is normally
induced at E15.523 co-incident with the rise in cardiac
corticosterone levels, which are negligible at E14.5.5 To test
whether glucocorticoids can induce Ppargc1a in vivo, dex-
amethasone was injected into pregnant dams at E14.5.
Within 6 h, steady-state levels of Ppargc1a mRNA were
increased in foetal hearts, as were levels of Fkbp5 mRNA, a
well-known GR target (Figures 5a and b), confirming
glucocorticoid regulation in vivo. To determine whether
PGC-1α induction is critical for glucocorticoids to elicit foetal
cardiomyocyte maturation, PGC-1α siRNA was used to
reduce Ppargc1a mRNA levels ~ 60%, abolishing the normal
increase in Ppargc1a mRNA levels following glucocorticoid
treatment (Supplementary Figure 4A). This reduction of
Ppargc1a mRNA in glucocorticoid-treated cardiomyocytes,
to reach the same level as in untreated cells, markedly
Figure 4 Glucocorticoids act viaGR to exert transcriptional effects on primary-mouse-foetal cardiomyocytes. GR siRNA or pretreatment with RU486 (10 μM, 30 min) blocked
or attenuated the dexamethasone (1 μM, 24 h) induction of mRNAs encoding GILZ (a), ANP (b), MyHCα (c) and PGC-1α (d). Cycloheximide (CHX, 10 μM, 30 min) pretreatment
blocked the glucocorticoid induction of MyHCα and ANP, but not GILZ or PGC-1α. Data were analysed by two-way ANOVA with Bonferroni multiple comparisons post-hoc test;
*Po0.05, **Po0.01, ***Po0.001 versus untreated; +Po0.05, ++Po0.01,+++Po0.001 versus dex; n= 4 replicates. Statistical significance versus dex is only indicated for
dexamethasone-treated groups
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attenuated the effect of corticosterone on myofibrillar
structure, sarcomere length and Z-disc width (Figure 6).
In contrast, PGC-1α knock-down had no significant effect
on glucocorticoid induction of Tsc22d3, Nppa, or Myh6
(Supplementary Figure 3C), nor, importantly, did it affect
Nr3c1 (GR) mRNA or protein levels (Supplementary Figure 3B).
The GR-mediated induction of PGC-1α increases oxygen
consumption rate in primary foetal cardiomyocytes.
The known role of PGC-1α in mitochondrial gene
expression33 suggested that glucocorticoids promote mito-
chondrial function and/or capacity in foetal cardiomyocytes.
To test this, the oxygen consumption rate (OCR) wasmeasured
following 100 nM corticosterone treatment for 24 h. OCR was
higher in corticosterone-treated cells, an effect attenuated by
RU486 (Figure 7a) indicating GR activation increases cellular
respiration. Knock-down of PGC-1α eliminated the effect of
corticosterone on OCR but had no effect in its absence
(Figure 7b), demonstrating that the glucocorticoid-mediated
promotion of mitochondrial function as well as cardiomyocyte
structure depends upon PGC-1α induction. Corticosterone also
enhanced the mitochondrial capacity of foetal cardiomyocytes
as shownbya greater increase inOCR following addition of 2,4-
dinitrophenol to uncouple mitochondrial respiration from ATP
synthesis (Supplementary Figure 5).
Table 1 Differentially expressed genes were subject to gene set enrichment analysis with gene ontology terms affecting molecular function
P-value Expected
count
Count Size Genes (fold-change)
GO:0003700: sequence-specific DNA binding transcription factor activity
1.392×10− 6 14.523 35 393 Klf5 (3.07), Runx1t1 (2.01), Cebpb (3.13), Arid3a (−1.67), Elf3 (−4.92), Epas1 (1.51),
Erf (3.45), Tsc22d3 (2.11), Nr3c1 (−1.47), Gsc (18.48), Hand2 (1.58), Hes1 (−3.73),
Hey1 (−3.38), Hlx (3.43), Id3 (−2.01), Irf1 (−1.61), Klf2 (1.72), Mafb (−3.21), Lhx6 (7.40),
Mycl1 (6.53), Aff1 (2.15), Mnt (−1.85), Myc (2.09), Nfe2l3 (−1.68), Mycn (−1.47), Notch1
(2.07), Pitx3 (38.36), Ppara (2.93), Prox1 (−1.72), Six1 (2.56), Sox12 (−1.55), Sox4 (1.97),
Bhlhe40 (−1.99), Tfdp2 (2.88), Csrnp1 (2.22), Hlf (2.08), Nr1d1 (−1.62), Rarb (−1.62),
Vdr (4.02), Wt1 (2.10), Tgif2 (−1.68), Grhl3 (1.81), Zbtb16 (61.17), Nr0b2 (1.62), Hif3a (7.36),
Heyl (−2.01), Foxo3 (2.68), Elf4 (−1.81), Klf15 (3.07), Tcfap4 (−1.70), Glis2 (−1.91)
GO:0043565: sequence-specific DNA binding
2.48×10−5 17.238 36 458 Cebpb (3.13), Elf3 (−4.92), Epas1 (1.51), Erf (3.45), Nr3c1 (−1.47), Gsc (18.48), Hand2 (1.58),
Hes1 (−3.73), Hey1 (−3.38), Hlx (3.43), Irf1 (−1.61), Klf2 (1.72), Mafb (−3.21), Lhx6 (7.40),
Myc (2.09), Nfe2l3 (−1.68), Notch1 (2.07), Per1 (6.08), Pitx3 (38.36), Ppara (2.93), Prox1
(−1.72), Scx (−1.61), Six1 (2.56), Sox12 (−1.55), Sox4 (1.97), Hlf (2.08), Nr1d1 (−1.62),
Rarb (−1.62),Vdr (4.02),Wt1 (2.10),Tgif2 (−1.68), Heyl (−2.01), Foxo3 (2.68), Elf4 (−1.81),
Ctcfl (2.13), Tcfap4 (−1.70)
GO:0070888: E-box binding
4.932×10− 5 0.715 6 19 Hand2 (1.58), Myc (2.09), Per1 (6.08), Scx (−1.61), Bhlhe40 (−1.99), Tcfap4 (−1.70)
GO:0000981: sequence-specific DNA binding RNA polymerase II transcription factor activity
0.0007 6.436 16 171 Cebpb (3.13), Hand2 (1.58), Hes1 (−3.73), Ppara (2.93), Prox1 (−1.72), Sox12 (−1.55),
Sox4 (1.97), Bhlhe40 (−1.99), Rarb (−1.62), Vdr (4.02), Wt1 (2.10), Grhl3 (1.81), Heyl (−2.01),
Foxo3 (2.68), Tcfap4 (−1.70), Glis2 (−1.91)
GO:0000975: regulatory region DNA binding
0.0021 9.823 20 261 Nr3c1 (−1.47), Hand2 (1.58), Hes1 (−3.73), Hlx (3.43), Irf1 (−1.61), Myc (2.09), Per1 (6.08),
Prox1 (−1.72), Scx (−1.61), Six1 (2.56), Sox12 (−1.55), Sox4 (1.97), Bhlhe40 (−1.99), Nr1d1
(−1.62), Wt1 (2.10), Heyl (−2.01), Ctcfl (2.13), Tbl1xr1 (1.83), Tcfap4 (−1.70), Glis2 (−1.91)
GO:0001077: RNA polymerase II core promoter proximal region sequence-specific DNA binding transcription factor
0.0028 1.9195 7 51 Cebpb (3.13), Hand2 (1.58), Sox12 (−1.55), Sox4 (1.97), Wt1 (2.10), Heyl (−2.01), Glis2 (−1.91)
GO:0000988: protein binding transcription factor activity
0.0074 11.742 21 312 Elf3 (4.92), Lpin1 (1.66), Nr3c1 (−1.47), Hand2 (1.58), Hey1 (−3.38), Jub (−2.14), Ppargc1b
(−1.85), Per1 (6.08), Per2 (1.95), Ppargc1a (1.97), Prox1 (−1.72), Sox12 (−1.55), Sox4 (1.97),
Bhlhe40 (−1.99), Nr0b2 (1.62), Irf2bp2 (1.88), Heyl (−2.01), Cited4 (−1.58), Sertad2 (−1.62),
Med26 (2.46), Tbl1xr1 (1.83)
GO:0008134: transcription factor binding
0.0153 13.361 22 355 Cebpb (3.13), Epas1 (1.51), Lpin1 (1.66), Tsc22d3 (2.11), Nr3c1 (−1.47), Hand2 (1.58),
Hes1 (−3.73), Id3 (−2.01), Id4 (2.21), Mafb (−3.21), Myc (2.09), Nab2 (−1.97), Nfkbia (3.04),
Ppara (2.93), Ppargc1a (1.97), Scx (−1.61), Bhlhe40 (−1.99), Tfdp2 (2.88), Vdr (4.02),
Nr0b2 (1.62), Foxo3 (2.68), Tob2 (5.03)
GO:0003712: transcription cofactor activity
0.0427 10.764 17 286 Elf3 (4.92), Lpin1 (1.66), Nr3c1 (−1.47), Hand2 (1.58), Jub (−2.14), Ppargc1b (−1.85),
Ppargc1a (1.97), Prox1 (−1.72), Sox12 (−1.55), Sox4 (1.97), Nr0b2 (1.62), Irf2bp2 (1.88),
Heyl (−2.01), Cited4 (−1.58), Sertad2 (−1.62), Med26 (2.46), Tbl1xr1 (1.83)
GO terms are indicated, with expected and actual gene counts and P-value. Differentially expressed genes are listed with fold-change (dex/control; repression shown
as a negative fold-change) indicated in brackets
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Figure 5 Dexamethasone increases steady-state levels of Ppargc1a (PGC-1α) and Fkbp5 mRNA after 6 h in E14.5 foetal heart. Dexamethasone (500 μg/kg body weight)
was administered to pregnant mothers by peritoneal injection at E14.6. Foetal tissues were collected after 6 h. Data were analysed by Student’s t-test; ***Po0.001; n= 22
foetuses (from six pregnant dams per group)
Figure 6 Corticosterone-induced maturation of myofibril structure is abrogated by PGC-1α knock-down. Cells were untreated (control; left panels) or treated with 100 nM
corticosterone for 24 h (cort; centre panels). To block PGC-1α-mediated effects, cells were transfected with PGC-1α siRNA 40 h prior to glucocorticoid treatment (right
panels). Cells were fixed and stained for α-actinin (red). DAPI (blue) was used as a nuclear counterstain. Images representative of n= 25–120 cells. Images were also scored
for myofibrillar structure (as described in Materials and Methods). PGC-1α knock-down abrogated corticosterone induced increases in myofibrillar structure score
(top graph), sarcomere length (middle graph) and Z-disc width (bottom graph). Data were analysed by one-way ANOVA with Bonferroni’s post-hoc test; +/&Po0.05,
**/++/^^/&&Po0.01, ***/+++/^^^Po0.001; *versus untreated control, +versus dex, ^versus scambled PGC-1α siRNA, and versus PGC-1α siRNA; n= 25–120 replicates over
two independent experiments
Glucocorticoids promote foetal cardiomyocyte maturation
EA Rog-Zielinska et al
1112
Cell Death and Differentiation
Discussion
At a physiologically relevant concentration, corticosterone
improved the contraction-relaxation properties of primary
foetal cardiomyocytes and elicited a striking maturation of
myofibrillar content and organisation. This mirrors the in vivo
situation where the absence of GR signalling in foetal
cardiomyocytes impairs contraction and results in short,
disorganised myofibrils with poorly defined Z-discs,5 suggest-
ing similar mechanisms for glucocorticoid maturation of
cardiomyocyte structure and function in vivo as in vitro.
The glucocorticoid-mediated improvement in contraction-
relaxation properties is likely underpinned by improved
calcium handling as well as structural changes in myofibrils.
As observed in vivo,5 glucocorticoid action increased expres-
sion of genes encoding the calcium handling proteins
SERCA2a and RYR2 as well as contractile proteins (MyHCα)
in primary foetal cardiomyocytes. This glucocorticoid induction
of mRNAs encoding proteins involved in calcium-induced
calcium-release accords with previous findings that glucocor-
ticoids increase cardiac L- and T-type calcium current
amplitude and channel density in rat neonatal
cardiomyocytes.34–37 Moreover, cardiomyocytes isolated from
E18.5 GR− /− foetuses have lower peak calcium channel
amplitude,38 further supporting a role for glucocorticoid action
in regulating sarcolemmal calcium flux. Apart from genes
involved in cardiomyocyte depolarisation and initiation of
contraction, our data suggest glucocorticoids also promote the
later stages of cardiac excitation-contraction coupling, as
dexamethasone increased mRNA encoding NCX and several
voltage-gated potassium channels, vital for cardiomyocyte
repolarisation. However, whilst the RNAseq implicated genes
encoding potassium channels as primary GR targets, genes
encoding calcium handling proteins were not differentially
expressed, and hence their induction by glucocorticoids in
foetal cardiomyocytes is most likely a secondary effect of GR
signalling.
Glucocorticoid treatment dramatically improved myofibril
appearance in foetal cardiomyocytes. The redistribution of
α-actinin, from the diffuse punctate staining pattern of
untreated foetal cardiomyocytes to the well-defined Z-discs
in corticosterone-treated cells probably reflects the fusion of
Z-bodies of immature pre-myofibrils to form the Z-discs in
mature myofibrils.39 In a previous electron microscopy study,
contractile filaments were confined to the periphery of rat
foetal (E20) myocytes and lacked sarcomeres whereas
neonatal rat myocytes contained sarcomeres,8 consistent
with more mature myofibril structure in neonatal cardio-
myocytes compared to foetal. This structural aspect of
glucocorticoid-promoted cardiomyocyte maturation depends
on glucocorticoid induction of Ppargc1a though other aspects
of cardiomyocyte maturation also seen in vivo (Myh6 and
Nppa induction) are not and are presumablymediated by other
GR-induced transcription regulators. In a recent report, knock-
down of PGC-1α or uncoupling of mitochondrial activity by
2,4-dinitrophenol in hESC cardiomyocytes diminished the
α-actinin banding pattern of contractile filaments,24 an effect
strikingly similar to that we observed following PGC-1α knock-
down in glucocorticoid-treated foetal cardiomyocytes. Given
that PGC-1α knock-down also reduced mitochondrial volume
and activity in hESC cardiomyocytes,24 this strongly suggests
that a PGC-1α-driven increase in mitochondrial capacity
promotes contractile function through improved sarcomeric
integrity, as cardiomyocytes mature. Indeed, glucocorticoid
treatment increased basal respiration in foetal cardiomyocytes
in a PGC-1α-dependent manner, consistent with the PGC-1α-
driven effects on both myofibrillar structure and mitochondrial
capacity in hESC cardiomyocytes24 as well as data from rat
neonatal cardiomyocytes showing that dexamethasone
increases both intracellular ATP levels and capacity to
synthesise ATP.40 PGC1-α also promotes production of
reactive oxygen species (ROS) in hESC-derived
cardiomyocytes.24 Interestingly, FOXO3, important for resis-
tance to oxidative stress in cardiomyocytes,41 was increased
in our RNAseq, suggesting glucocorticoid action concurrently
induces the processes that generate ROS as well as
mechanisms to alleviate the potential damage they may
Figure 7 Glucocorticoids act via GR and PGC-1α to increase mitochondrial respiration in primary foetal cardiomyocytes. Real-time oxygen consumption rate (OCR) was
measured in untreated (control) foetal cardiomyocytes or following treatment with 100 nM corticosterone for 24 h (cort). Cells were pre-treated with RU486 (1 μM, 30 min) or
transfected with PGC-1α siRNA (40 h). Data were analysed by one-way ANOVA with Bonferroni’s post-hoc test; *Po0.05 versus control, +Po0.05 versus cort
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cause. PGC-1α is already expressed in mouse foetal heart at
E15.5,23 suggesting it may act as a GR coactivator42,43 and/or
acts downstream of GR to enhance metabolic maturation of
foetal cardiomyocytes. Our data support PGC-1α as down-
stream and a direct target of GR but do not eliminate a role as a
coactivator of GR. Indeed, a recent study in mouse islets
showed that PGC-1α is both a target and a co-regulator of GR,
with downstream effects dependent on the presence of both at
regulated promoters.44 A similar co-dependence in foetal
cardiomyocytes might ensure that although expressed,
PGC-1α does not exert its full biological effects until
corticosterone levels rise and GR is activated. How GR
induces Ppargc1a is currently unclear. We were unable to
show glucocorticoid regulation of luciferase reporter con-
structs containing ~4 kb of the Ppargc1a promoter, despite it
being glucocorticoid inducible in mouse BWTG3 hepatoma
cells (unpublished data), thus the glucocorticoid responsive
element must lie outside of this region.
The postnatal heart heavily relies on oxidative catabolism of
fatty acids to produce energy.45 Our data support the view that
glucocorticoid action in late gestation drives this maturation of
cardiac energy metabolism. In addition to PGC-1α induction
and independently of new protein synthesis, dexamethasone
increased expression of master regulators of lipid/fatty acid
oxidation in foetal cardiomyocytes: PPARα, Klf15, and lipin 1.
PPARα co-operates with PGC-1α to induce genes required for
fatty acid uptake and oxidation in themyocardium46 Lipin-1, an
amplifier of PGC-1α/PPARα mediated control of lipid metabo-
lism that promotes fatty acid oxidation and mitochondrial
oxidative phosphorylation in the liver47 may play a similar role
in heart, where it is both a transcriptional target of, and
coactivator of, PGC-1α.48 Klf15, a known GR target, regulates
amino acid, lipid, and glucose metabolism49–51 and acts with
GR to control feed-forward gene-regulatory circuits in lung.52
Klf15 is also a direct regulator of myocardial lipid flux, induced
in the mouse heart in the perinatal period.53 Thus glucocorti-
coid action induces a set of master transcriptional regulators
which themselves may act in concert with GR in feed-forward
circuits to increase cardiomyocyte ATP-generating capacity.
As well as master regulators of fatty acid oxidation, dexa-
methasone markedly induced Plin4, encoding perilipin 4, a
lipid droplet coating protein. Plin4 disruption in mice reduces
cardiac-lipid content,54 suggesting glucocorticoids promote
storage of energy substrate in cardiomyocytes as well as
increasing capacity to utilise it. It is interesting in this respect
that several Slc transporters were glucocorticoid-induced in
the presence of cycloheximide, suggesting increased sub-
strate flux into and around the cell as part of a co-ordinated
glucocorticoid-mediated increase in energy-generating capa-
city. A substantial minority of differentially expressed genes
were decreased following dexamethasone treatment in the
presence of cycloheximide. How this reduction in steady-state
mRNA levels occurs within 2 h is unclear. However, the
repressed genes include Hes1, a highly conserved transcrip-
tional repressor required for organogenesis55 and a master
regulator of GR-dependent gene expression.56 In liver, GR-
dependent antagonism of NFκB at the Hes1 locus, rapidly
silences HES1, increasing glucocorticoid sensitivity and
altering lipid and carbohydrate metabolism.56 Decreased
Hes1 expression in foetal cardiomyocytes may similarly
enhance glucocorticoid action, aiding metabolic maturation.
A number of the genes that we identified as glucocorticoid
regulated in foetal cardiomyocytes are glucocorticoid regu-
lated in other muscle-related cell types, including rat neonatal
cardiomyocytes, embryonic rat H9C2 myoblasts and mouse
C2C12 myotubes.30–32 However, despite similarities between
glucocorticoid-regulated genes in this and previous studies,
none show the same pattern of glucocorticoid-regulated gene
regulation, with the cell lines showing many differences to
foetal cardiomyocytes. Differences to neonatal rat cardiomyo-
cytes may reflect their prior exposure to glucocorticoid,
possibly altering subsequent responses.9 Remarkably, of the
173 glucocorticoid-induced genes identified as direct targets
of GR in C2C12 cells, only a third of the induced genes and
none of the repressed genes showed similar regulation in
foetal mouse cardiomyocytes; three even showed the oppo-
site regulation. Although some of this variation may relate to
experimental conditions, the data are consistent with previous
demonstrations of the highly cell-specific repertoire of GR-
regulated genes,10,57,58 and illustrate the importance of
establishing the glucocorticoid-regulated transcriptome within
the relevant primary cell.
These data have wider implications. Despite the routine use
of glucocorticoids in preterm babies, little is known of how
effects on heart contribute to improved survival of neonates.
Our experiments have identified early molecular events
triggered by glucocorticoid action in cardiomyocytes during
late foetal development and highlight mechanisms likely to be
critical for maturation and thus resilience of the foetal heart, in
the perinatal period.
Materials and Methods
Animals; in vivo dexamethasone administration. All animal experi-
mentation was carried out in strict accord with accepted standards of humane
animal care under the auspices of the Animal (Scientific Procedures) Act UK 1986
after prior approval by the University of Edinburgh Animal Ethical Review
Committee.
Female C57BL/6 mice were maintained under conditions of controlled lighting and
temperature. Time-mated females were injected intra-peritoneally with 500 μg/kg
dexamethasone or vehicle (saline) at E14.5 then culled 6 h post-injection. Foetal
hearts were collected and stored at − 80 °C prior to RNA analysis.
Cardiomyocyte cultures. Primary mouse (Mus musculus) foetal cardiomyo-
cytes were isolated from the ventricles of E15.5–E17.5 C57BL/6 foetal hearts and
cultured as described,59 except that 0.3 mg/ml collagenase II (Worthington,
Lakewood, NJ, USA) was added to the enzyme buffer and cardiomyocytes were
cultured on gelatin-covered plates. Isolated cells were ≥ 98% troponin T-positive
cells (Supplementary Figure 1A) and when cultured, cells proliferated and beat
spontaneously and synchronously after ~ 2 days. Cells were treated with
dexamethasone or corticosterone (as stated in the figure legends), with 30 min
pretreatment with 10 μM cycloheximide or RU38486 (mifepristone) where
appropriate (all purchased from Sigma; Poole, UK). Control cells were treated
with vehicle only (96% ethanol). For siRNA knock-down, 40 h prior to
dexamethasone administration cells were transfected with GR or PGC-1α siRNA
(catalogue number s67065 and s72015, respectively; Ambion, Austin, TX, USA)
using Lipofectamine 2000 (Life Technologies, Paisley, UK) according to the
manufacturer’s instructions.
Soft-video edge detection. Mechanical properties of spontaneously
contracting cardiomyocytes were measured using an optical video edge-detection
system (Ionwizard, Ionoptix, Milton, MA, USA) with a heated stage (37 °C). Analysis
of magnitude and timecourse was performed with Origin6.1 (Originlabs Corporation,
Northampton, MA, USA).
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Immunohistochemistry and immunofluorescence. Cells grown on
glass coverslips were fixed in 4% paraformaldehyde and stained according to
standard protocols with anti-α-actinin antibody (Abcam, Cambridge, UK) or anti-α-
smooth muscle actin (α-SMA) antibody (Sigma) and troponin T (Abcam).
Fluorophore-conjugated secondary antibodies (Alexa Fluor, Life Technologies)
were used to detect immunostaining. Scoring of myofibrillar structure was carried
out on images by two or three people not involved in the experiment, who were blind
to treatment group, according to the following scores: 1= randomly scattered
punctuate or fuzzy appearance of Z-structures; 2= clearly visible sarcomeres
(striation, but myofibrils not well organised with indistinct Z-structures; and
3= clearly visible, distinct striation and wide discrete Z-discs, high degree of
myofibril alignment.
Electron microscopy. Cells grown on plastic coverslips were fixed in 3%
glutaraldehyde in 0.1 M sodium cacodylate, pH 7.3, post-fixed in 1% osmium
tetroxide in 0.1 M sodium cacodylate, then dehydrated and embedded in araldite
resin. Ultrathin (60 nm) sections were cut and stained in uranyl acetate and lead
citrate then viewed in a Phillips CM120 Transmission electron microscope (FEI UK,
Cambridge, England).
Quantitative (q)PCR. RNA was extracted using a PureLinkTM RNA Mini kit
(Life Technologies) according to the manufacturer’s instructions and reverse
transcribed using a Superscript First Strand Synthesis kit (Life Technologies).
Quantitative (q)PCR was carried out using a LightCycler 480 (Roche Diagnostics,
Burgess Hill, UK) with a commercial master mix (LC 480 Probes Master) using the
Universal Probe Library system (Roche Diagnostics; Table 2). Data were analyzed
using the second derivative maximum method. The ratio of levels of the transcript of
interest to levels of TATA Binding Protein (TBP) or β-actin mRNA (as internal control;
see figure legends) was determined for each sample.
Western blotting. GR levels were measured by western blot using 1 : 400
dilution rabbit anti-mouse GR primary antibody (M-20, Santa Cruz Biotechnology,
Dallas, TX, USA). Protein levels were measured relative to β-tubulin levels using an
Odyssey infra-red imaging system (Licor Biosciences, Lincoln, NE, USA).
RNAseq. RNAseq was performed by Edinburgh Genomics (University of
Edinburgh) on RNA extracted from primary foetal cardiomyocytes treated with
100 nM dexamethasone for 2 h in the presence of 10 μM cycloheximide. Control
cells were treated with cycloheximide alone. TruSeq (version 2; Illumina, San Diego,
CA, USA) libraries were prepared and sequenced using an Illumina HiSeq 2000
platform (Illumina UK, Little Chesterford, Essex, UK), generating 50 base single-end
sequences, yielding 30–50 M reads per sample. Reads were mapped using GSNAP
and assigned to exon features with the htseq-count utility of HTSeq60–62 (version
0.5.3) in 'union' mode, specifying a non-stranded library, a minimum quality of 20
and mouse genome version NCBI m37 (Ensembl 67) as reference annotation.
Counts were then normalised by effective library size, and differential expression
(count) assessed, with the use of the DESeq package60 (v. 1.9.7) from
Bioconductor.61 Normalised counts and differential expression measures were
placed in a database with in-house tools for data mining. Data were analysed based
on fold-change and statistical significance. Enrichment of GO terms in differentially
expressed gene sets was assessed with the hypergeometric statistic as
implemented in the GOstats package62 (v 2.24.0) of Bioconductor.
Cellular bioenergetics analysis. OCR values were measured in real time
in primary foetal cardiomyocytes using a Seahorse XF-24 bioanalyser (Seahorse
Bioscience, North Billerica, MA, USA). Cells were seeded at a density of ~ 75 000
per well in a XF-24 microplate 24 h prior to analysis and treated with corticosterone
and/or RU38486 or transfected with PGC-1α siRNA as described above. One hour
prior to analysis media was changed to unbuffered DMEM and cells were incubated
at 37 °C in 0% CO2. Analysis was performed according to the manufacturer’s
instructions using an XF assay kit (Seahorse BioScience). Three OCR
measurements (performed every 6 min) were recorded. To measure mitochondrial
reserve, following measurement of OCR, 100 μM 2,4-dinitrophenol was injected and
then two subsequent measurements were made. Following the assay, cells were
trypsinized and counted, and the OCR values corrected for the cell number.
Statistics. All numerical data are presented as mean± S.E.M. Statistical
evaluation was carried out with Prism (GraphPad) and used Students t-test, one-
way ANOVA with Bonferroni’s post-hoc test or two-way ANOVA with Bonferroni’s
multiple comparisons post-hoc test, or area under the curve analysis, as
appropriate.
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